Abstract: To observe the curative effects of oxaliplatin combined with capecitabine on the therapy of post-operative patients with advanced gastric carcinoma and its effects on the lymphocyte subcluster. Methods: A total of 84 post-operative patients with advanced gastric carcinoma from 2007 to 2009 in our hospital were divided into the observation group and the control group based on the sequence of hospitalization. XELOX ( oxaliplatin with capecitabine ) was used in the observation group. FOLFOX was used in the control group. The adverse effects, one-year survival rate, and progression-free survival time were observed. The lymphocyte subcluster was determined. Results: The incidence rates of hypoleukocytosis, nausea, and vomiting in the observation group were significantly lower than those in the control group. The incidence rates of diarrhea and neurovirulence had no differences between these two groups. The incidence of hand and foot syndrome in the observation group was significantly higher than that in the control group. The chemotherapy cycle was 3.93 ± 0.42, with a one-year survival rate of 83.3%, and a progression-free survival time of 9.1 ± 2.3 months in the observation group, which were significantly better than those in the control group. The proportion of CD3+ and CD4+ T cells and the ratio of CD4+/CD8+ were significantly increased and the proportion of CD4+CD25+ T cells were significantly decreased after chemotherapy ( P < 0.05 ). The changes were more significant in the observation group than those in the control group. Conclusion: Oxaliplatin with capecitabine could improve the immunosuppression condition, recovery of the ratio of lymphocyte sub-cluster, and obtain a satisfactory curative effect in postoperative patients with advanced gastric carcinoma.